



FOR IMMEDIATE RELEASE

Tokyo, August 21, 2023

JT's License Partner LEO Pharma Announced that the European Medicines Agency Accepts Marketing Authorization Application for Delgocitinib Cream, a Topical JAK Inhibitor

Japan Tobacco Inc. (JT) (TSE:2914) today announced that LEO Pharma A/S (LEO Pharma) issued a statement that the European Medicines Agency (EMA) has accepted its marketing authorization application (MAA) for delgocitinib cream, a topical Janus kinase (JAK) Inhibitor, for the treatment of chronic hand eczema on August 17, 2023.

About Delgocitinib

Delgocitinib is a non-steroidal, JAK inhibitor that is expected to improve autoimmune and allergic diseases by inhibiting the action of JAKs, which play key roles in immune activation signaling in cells, by suppressing the overactivation of immune responses.

Delgocitinib was originated by JT. In 2014, JT and LEO Pharma entered into a license agreement in which LEO Pharma gained exclusive rights to develop and commercialize delgocitinib for topical use in dermatological indications worldwide, excluding Japan.

Torii Pharmaceutical Co., Ltd. distributes delgocitinib under the brand name CORECTIM® in Japan, where CORECTIM® Ointment 0.5% is approved for the treatment of adults and pediatric atopic dermatitis, and CORECTIM® Ointment 0.25% is approved for the treatment of pediatric atopic dermatitis.

About Chronic Hand Eczema

Chronic hand eczema (CHE) is defined as hand eczema that lasts for more than three months or relapses twice or more within a year. CHE is a fluctuating disorder characterized by itch and pain, and patients may experience signs such as erythema, scaling, lichenification, hyperkeratosis, vesicles, edema, and fissures on hands and wrists.

###

Japan Tobacco Inc. is a leading international tobacco and vaping company and its products are sold in over 130 markets. With approximately 53,000 employees, it manufactures and sells some of the world's best-known brands including Winston, Camel, MEVIUS and LD. The JT Group is committed to investing in Reduced-Risk Products (RRP) and currently markets its heated tobacco products under its Ploom brand and various e-cigarette products under its Logic brand. The Group is also present in the pharmaceutical and processed food businesses. For more information, visit <https://www.jt.com/>.

Contact: Ichiro Kawai, Director
Manabu Hirose, Associate Manager
Media and Investor Relations Division
Japan Tobacco Inc.
Tokyo: +81-3-6636-2914
E-mail: jt.media.relations@jt.com